CN115010785A - Tetrapeptide with dipeptidyl peptidase-4 inhibitory activity and application thereof - Google Patents
Tetrapeptide with dipeptidyl peptidase-4 inhibitory activity and application thereof Download PDFInfo
- Publication number
- CN115010785A CN115010785A CN202210528272.3A CN202210528272A CN115010785A CN 115010785 A CN115010785 A CN 115010785A CN 202210528272 A CN202210528272 A CN 202210528272A CN 115010785 A CN115010785 A CN 115010785A
- Authority
- CN
- China
- Prior art keywords
- tetrapeptide
- inhibitory activity
- dipeptidyl peptidase
- dpp
- mgpr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 title claims abstract description 43
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 title claims abstract description 43
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 52
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 20
- 229920001184 polypeptide Polymers 0.000 claims abstract description 12
- 238000010532 solid phase synthesis reaction Methods 0.000 claims abstract description 10
- 102000008186 Collagen Human genes 0.000 claims abstract description 9
- 108010035532 Collagen Proteins 0.000 claims abstract description 9
- 229920001436 collagen Polymers 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 206010012601 diabetes mellitus Diseases 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 4
- -1 Arg amino acid Chemical class 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 2
- 235000013402 health food Nutrition 0.000 claims 1
- 238000012216 screening Methods 0.000 abstract description 9
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 7
- 238000000338 in vitro Methods 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 238000001514 detection method Methods 0.000 abstract description 2
- 231100000956 nontoxicity Toxicity 0.000 abstract description 2
- 238000005094 computer simulation Methods 0.000 abstract 1
- 235000013376 functional food Nutrition 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
- 206010022489 Insulin Resistance Diseases 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000004190 glucose uptake Effects 0.000 description 6
- 238000003032 molecular docking Methods 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229960002442 glucosamine Drugs 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000003041 virtual screening Methods 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 102100040918 Pro-glucagon Human genes 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- IHUKVJKKTBLTEE-QMMMGPOBSA-N (2s)-2-acetamido-5-[[amino-(methylcarbamoylamino)methylidene]amino]-n-methylpentanamide Chemical compound CNC(=O)NC(N)=NCCC[C@H](NC(C)=O)C(=O)NC IHUKVJKKTBLTEE-QMMMGPOBSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- FZHXIRIBWMQPQF-VANKVMQKSA-N L-glucosamine Chemical compound O=C[C@@H](N)[C@H](O)[C@@H](O)[C@@H](O)CO FZHXIRIBWMQPQF-VANKVMQKSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002473 insulinotropic effect Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000010958 polyglycerol polyricinoleate Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a dipeptidyl peptidase-4 (DPP-4) inhibitory peptide derived from yak collagen, wherein the amino acid sequence of the peptide isMet-Gly-Pro-Arg, abbreviated MGPR. The invention utilizes different online databases and adopts a computer simulation method to carry out multiple rounds of screening, and finally obtains a peptide segment with DPP-4 inhibitory activity. The polypeptide of the invention can be chemically synthesized by a solid phase synthesis method, and has purity>98 percent, small molecular weight, convenient artificial synthesis, good water solubility, no toxicity, high safety and the like. In vitro DPP-4 inhibitory activity detection shows that the tetrapeptide MGPR inhibits DPP-4 by 50 percent (IC) 50 ) Is 0.225 mg/mL; can be used for developing functional food with DPP-4 inhibitory activity and synthesizing hypoglycemic treatment drugs.
Description
Technical Field
The invention relates to the field of bioactive peptides, in particular to a tetrapeptide with dipeptidyl peptidase-4 inhibitory activity and application thereof.
Background
Diabetes is a high-risk chronic disease, and in recent years, with the development of socioeconomic, the dietary structure and the life style of people change, and the incidence rate of diabetes, particularly type II diabetes, is increasing year by year. In 2030, the number of people suffering from diabetes mellitus is 4 hundred million, wherein diabetes mellitus type II accounts for the majority, and accounts for about 90%, and various clinical treatment medicines are easy to cause various side effects such as hypoglycemia, hypotension, liver injury and the like, so that the development of a novel food-borne active substance for adjuvant treatment of diabetes mellitus has a very important application prospect. Several studies have shown that bioactive peptides have an effect on improving diabetes. For example, in the research of the Wangweibo and the like, the marine collagen peptide can relieve the structural damage of islet beta cells of a rat with hyperinsulinemia, increase the secretion of particles, reduce the formation of lipid droplets and obviously improve the biological activity of insulin; it also has certain improving effect on fasting blood glucose and oral glucose tolerance.
Dipeptidyl peptidase-4 (DPP-4) is a serine protease, which can cleave Xaa-Pro or Xaa-Ala structure at the N-terminal of peptides such as hormones, and glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic hormone (GIP) can promote the secretion of insulin of the body and inhibit the secretion of glucagon in the process of diabetes, and has important effects in regulating the blood sugar balance of the human body. The DPP-4 is found to cut off two amino acids at the amino terminal of GLP-1 and GIP, so that the physiological function of the GLP-1 and the GIP is lost, and the blood sugar regulation is influenced. Therefore, inhibiting the activity of DPP-4 is beneficial to control blood sugar level, and DPP-4 inhibitors have become a hotspot for research on diabetes treatment.
At present, the traditional enzymolysis-separation-purification method is mainly adopted to screen and identify the hypoglycemic peptide, the process is complicated, the time consumption is long, a large amount of manpower and material resources are consumed, the yield is low, and certain monopeptide with strong activity is easy to miss due to the segmented activity determination method. Therefore, it is necessary to find a method for efficiently finding active peptides to realize mass production.
Disclosure of Invention
Aiming at the problems in the prior art, the invention provides a hypoglycemic tetrapeptide with DPP-4 inhibitory activity and application thereof. The active peptide sieve is selected from yak type I collagen sequences, the screened peptide is obtained by solid phase synthesis, a DPP-4 and HepG2 (human hepatoma cell) cell insulin resistance model is taken as a research object, the in-vitro blood glucose reduction effect of the synthetic peptide is detected, and the result shows that the peptide has better DPP-4 inhibitory activity and IC 50 Is 0.225mg/mL, can obviously improve the insulin resistance phenomenon, promotes the absorption of glycogen, and has certain hypoglycemic effect.
The technical scheme of the invention is as follows:
a tetrapeptide having dipeptidyl peptidase-4 inhibitory activity, said tetrapeptide being abbreviated as MGPR, the amino acid sequence of said tetrapeptide being Met-Gly-Pro-Arg.
The molecular weight of the tetrapeptide is 459.56 Da.
The tetrapeptide is of a single-chain linear structure, is white powder and is easily soluble in water.
The tetrapeptide is derived from yak collagen.
Inhibitory Activity IC of the tetrapeptides on dipeptidyl peptidase-4 50 It was 0.225 mg/mL.
The tetrapeptide is chemically synthesized by a solid phase synthesis method, and the purity is more than 98%.
Further, the solid phase synthesis method comprises the following steps:
according to the characteristics of an amino acid sequence Met-Gly-Pro-Arg, a carboxyl group of Met is firstly connected with a resin in a covalent bond mode, then an amino group of Met and a carboxyl group of Gly are subjected to a glycidyl reaction, Pro, an amino group of Gly and a carboxyl group of Pro are added for a reaction after treatment, then the last Arg amino acid is added, the resin is removed after the reaction, and the MGPR is purified through high performance liquid chromatography to obtain the target polypeptide.
A pharmaceutical composition comprising said tetrapeptide having dipeptidyl peptidase-4 inhibitory activity.
An application of the tetrapeptide with the dipeptidyl peptidase-4 inhibitory activity in preparing the drugs for preventing and treating diabetes.
An application of the tetrapeptide with the dipeptidyl peptidase-4 inhibitory activity in preparing health-care food for preventing and treating diabetes.
The invention utilizes a bioinformatics method and various online active peptide databases to screen new hypoglycemic peptide from yak collagen. Firstly, performing virtual enzymolysis on yak collagen to obtain an enzymolysis peptide segment, screening unreported 2-5 peptides from the enzymolysis peptide segment, then predicting properties such as bioactivity score, molecular weight, water solubility, ADMET (absorption, distribution, metabolism, excretion and toxicity) and the like of the screened sequence, and performing molecular docking by using Discovery studio2019 software.
The result shows that the tetrapeptide MGPR has good water solubility, no toxicity, good small intestine absorption and good blood brain barrier permeability, and can be tightly combined with the key active site of DPP-4. The screened active peptide is synthesized by adopting a solid phase synthesis method, and the in-vitro DPP-4 inhibitory activity of the synthesized peptide is verified.
Advantages and technical effects of the invention
1. The invention carries out virtual screening of the directional combined polypeptide by the computer-aided technology, and compared with the traditional technology for preparing the active peptide by an enzymolysis method, the method adopted by the invention not only reduces the screening strength, shortens the research and development period, but also improves the probability of successful screening.
2. Through the search of an online database, the peptide sequence provided by the invention is not reported by a paper, and the tetrapeptide provided by the invention is a novel food-borne hypoglycemic peptide.
3. The tetrapeptide MGPR is synthesized by a solid-phase synthesis method, the in-vitro DPP-4 inhibitory activity of the synthesized peptide is detected, and the result shows that the synthesized peptide has potential blood sugar reducing capacity.
Drawings
FIG. 1 is a molecular docking diagram of a tetrapeptide MGPR and DPP-4;
FIG. 2 is a high performance liquid chromatogram of the synthetic polypeptide MGPR;
FIG. 3 is a mass spectrum of a synthetic polypeptide MGPR;
FIG. 4 shows the inhibitory activity of the synthetic polypeptide MGPR on DPP-4;
FIG. 5 shows the effect of the synthetic polypeptide MGPR on glucose uptake by HepG2 cells.
Detailed Description
The invention is described in detail below with reference to the figures and examples.
Example 1:
virtual screening of active peptides:
1. acquisition of Yak collagen sequence
Searching a collagen sequence from a yak source from a National Center for Biotechnology Information (NCBI) protein database, and finally selecting two chains of a yak type I collagen sequence: alpha-1(I) chain (Access: ELR60286.1) and alpha-2(I) chain (Access: ELR 46121.1).
2. Simulating gastrointestinal enzymolysis
The method comprises the steps of performing simulated enzymolysis on a yak collagen sequence by using ExPASY Peptidecter (https:// web. ExPASy. org/peptide _ cutter), selecting two digestive enzymes of pepsin (pH1.3) (EC 3.4.23.1) and trypsin (EC 3.4.21.4) to simulate human gastrointestinal tract digestive enzymolysis, screening 2-5 peptides from peptide segments generated by enzymolysis, comparing the peptides with an online database, screening unreported peptides, and performing next virtual screening.
3. Prediction of biological activity, water solubility, ADMET properties.
The bioactive potential of the selected active Peptide fragments was evaluated using the PeptideRanker (http:// distilldeep. ucd. ie/PeptideRanker /) program, the Peptide fragments with high scores were selected, the molecular weight and isoelectric point of the Peptide were predicted using the pI/Mw tool of the online software Expass (http:// web. Expasy. org/computer _ pI /), the net charge and hydrophobicity of the Peptide were predicted by Pepdraw (http:// www.tulane.edu/. about. biochem/WW/Pepdraw), and the water solubility of the Peptide was predicted using the "Peptide property calculator" function in the Innovagen program (http:// www.innovagen.com/proteomics-tools). ADMET properties are predicted by ADMETlab2.0(https:// admeash. scbdd. com /), and Human Intestinal Absorption (HIA), blood-brain barrier penetration (BBB) and acute oral toxicity are mainly used as analysis indexes. Finally, 5 peptide fragments GHR, GIR, PGPK, PGMK, MGPR and PGPR are selected to have better water solubility and ADMET properties, and the results are shown in table 1.
TABLE 1 bioactivity score, physicochemical and ADMET property prediction
4. Molecular docking screening DPP-4 inhibitory active peptide
The screened peptide fragment and DPP-4(PDB ID:5J3J) are subjected to molecular docking by using Discovery studio2019 software, and finally, a tetrapeptide MGPR with the best docking effect is selected. The existing research shows that DPP-4 has 3 key active pockets, the S1 active pocket is composed of Tyr547, Ser630, Tyr631, Val656, Trp659, Tyr662, Asn710, Val711 and His740, the S2 is composed of Glu205, Glu206 and Tyr662, Ser209, Arg358 and Phe357 constitute the S3 pocket, and the amino acid sites of the 3 active pockets are important targets for screening DPP-4 inhibitors. Docking results show that the tetrapeptide MGPR can be tightly combined with Ser630, His740, Tyr547 in the DPP-4S1 active pocket and Glu205 and Glu206 in the S2 pocket, form hydrogen bonds and electrostatic interaction, and can be combined with amino acid residues His126 and Arg125 of DPP-4 (FIG. 1). Finally, the in vitro activity verification is carried out on the synthesized polypeptide through the screened tetrapeptide synthesized by the solid phase.
Example 2:
artificial synthetic screened active peptide by solid phase synthesis method
The Fmoc solid-phase synthesis method is adopted, according to the characteristics of an amino acid sequence Met-Gly-Pro-Arg, the carboxyl of Met is firstly connected with a resin in a covalent bond mode, then the amino of Met and the carboxyl of Gly are subjected to a shrinking reaction, after treatment, the amino of Pro and Gly and the carboxyl of Pro are added for a reaction, then the last Arg amino acid is added, and after the reaction, the resin is cut off, so that the target polypeptide MGPR is obtained. Purification was performed by high performance liquid chromatography using a column model Kromasil C18, size 4.6 x 250mm, 5 μm, mobile phase a: acetonitrile containing 0.1% trifluoroacetic acid (TFA); mobile phase B: water with 0.1% TFA; the flow rate was 1.0mL/min, and the detection wavelength was 220 nm. The purity was required to be above 98% (as shown in fig. 2, table 2) and the structure was identified by MS (as shown in fig. 3).
TABLE 2
As shown in FIG. 3, the purity of the tetrapeptide MGPR was 98.11%, which meets the purity requirement of the synthetic peptide.
Example 3:
method for detecting in-vitro inhibitory activity of synthetic polypeptide MGPR on DPP-4
Detected using Sigma DPP-4 inhibitor screening kit (MAK 203).
Preparation of reagents
(1) Substrate solution: 200. mu.L of the crude product was diluted to 2.5mL with buffer solution and used in portions.
(2) Enzyme solution: 100 mu L of the original solution is diluted to 5mL by using a buffer solution and is subpackaged for use.
(3) Positive inhibitor (sitagliptin): 50 mu.L of the crude product is diluted to 0.5mL by using a buffer solution and is subpackaged for use.
(4) And (4) preparing a sample solution with gradient concentration by using a buffer solution.
The specific implementation steps are as follows: the reaction vessel was a black 96-well plate, 50. mu.L of the enzyme solution and 25. mu.L of the sample solution were added to the plate, the buffer solution was used for the enzyme control group, the sample solution was used for the positive inhibitor group, and the reaction was carried out at 37 ℃ for 10 min. Finally 25 μ L of substrate solution was added and the fluorescent FLU (FLU, λ ex 360/λ em 460) was measured every 1min during 15-30min after the reaction. A fluorescence value/time (min) curve is generated, and two time points (T) are selected in the linear range of the curve 1 And T 2 ) And obtaining T 1 And T 2 The slope of each hole in between. Determining the FLU (FLU) at a time 1 And an FLU 2 ) And used to determine the slope of the plot (Δ FLU/min).
Slope ═ FLU 2 –FLU 1 )/(T 2 –T 1 )＝FLU/minute
Relative inhibition (%) - (control slope-experimental slope)/control slope X100%
According to the calculated result, an inhibition rate-concentration curve is made to obtain IC 50 The value is obtained.
As can be seen from FIG. 4, the tetrapeptide MGPR had better DPP-4 inhibitory activity, IC 50 The value was 0.225 mg/mL.
Example 4:
effect of the synthetic polypeptide MGPR on HepG2 cell insulin resistance model
Establishment of insulin resistance model
Collecting HepG2 cells in logarithmic growth phase, removing culture solution, washing with PBS for 1 time, subjecting the cells to trypsinization to obtain cell suspension with density of about 1 × 10 5 The cell suspension was inoculated into a 96-well plate at a concentration of 100. mu.L/well and incubated at 37 ℃ with 5% CO 2 The cell culture box is used for adherent culture for 12 hours. The culture medium is discarded, 18mmol/L glucosamine is added for induction culture for 18h, and an insulin resistance model is established.
Grouping after the model is built, and respectively adding 100 mu L of complete culture solution into a blank group (without being treated by glucosamine) and a model group (treated by glucosamine); the administration groups were each added with 100. mu.L of peptide solutions (MGPR:25, 50, 100, 200, 400. mu. mol/L) of different concentrations. As a positive control, 10. mu. mol/L rosiglitazone was used. After 24h of administration treatment, taking the supernatant, and detecting the glucose content in the supernatant by adopting a glucose oxidase-peroxidase coupling method (GOD-POD), wherein the specific operation method refers to the instruction of a glucose kit. The glucose consumption was calculated as the formula:
glucose consumption-blank glucose content-test group glucose content
The experimental result shows that the glucose uptake of model group cells treated by glucosamine for 18h is reduced by 38.4% compared with that of a blank control group, which indicates that the establishment of the insulin resistance model is successful. After 24h of tetrapeptide MGPR treatment, the glucose uptake capacity of the cells was tested, and as shown in FIG. 5, the active peptide MGPR improves the glucose uptake in a dose-dependent manner, wherein the MGPR with the concentration of 400. mu. mol/L can obviously promote the glucose uptake of model cells, and the glucose uptake is improved by 35.6% compared with that of a model group.
Finally, it is also noted that the above-mentioned list is only a few specific embodiments of the present invention. It is obvious that the invention is not limited to the above embodiments, but that many variations are possible. All modifications directly derivable or suggested from the present disclosure are considered to be within the scope of the present invention.
Claims (10)
1. A tetrapeptide having dipeptidyl peptidase-4 inhibitory activity, wherein the tetrapeptide is abbreviated as MGPR and the amino acid sequence of the tetrapeptide is Met-Gly-Pro-Arg.
2. A tetrapeptide having dipeptidyl peptidase-4 inhibitory activity according to claim 1, wherein the tetrapeptide has a molecular weight of 459.56 Da.
3. The tetrapeptide having dipeptidyl peptidase-4 inhibitory activity according to claim 1, wherein the tetrapeptide has a single-chain linear structure, is in the form of a white powder, and is easily soluble in water.
4. The tetrapeptide having dipeptidyl peptidase-4 inhibitory activity according to claim 1, wherein the tetrapeptide is derived from yak collagen.
5. The tetrapeptide having dipeptidyl peptidase-4 inhibitory activity according to claim 1, wherein the tetrapeptide has dipeptidyl peptidase-4 inhibitory activity IC 50 It was 0.225 mg/mL.
6. The tetrapeptide having dipeptidyl peptidase-4 inhibitory activity according to claim 1, wherein the tetrapeptide is chemically synthesized by a solid phase synthesis method with a purity of > 98%.
7. A tetrapeptide having dipeptidyl peptidase-4 inhibitory activity according to claim 1, wherein the solid phase synthesis method is:
according to the characteristics of an amino acid sequence Met-Gly-Pro-Arg, a carboxyl group of Met is firstly connected with a resin in a covalent bond mode, then an amino group of Met and a carboxyl group of Gly are subjected to a glycidyl reaction, Pro, an amino group of Gly and a carboxyl group of Pro are added for a reaction after treatment, then the last Arg amino acid is added, the resin is removed after the reaction, and the MGPR is purified through high performance liquid chromatography to obtain the target polypeptide.
8. A pharmaceutical composition comprising the tetrapeptide having dipeptidyl peptidase-4 inhibitory activity according to claim 1.
9. Use of a tetrapeptide having dipeptidyl peptidase-4 inhibitory activity according to claim 1 for the preparation of a medicament for the prevention and treatment of diabetes.
10. Use of the tetrapeptide having dipeptidyl peptidase-4 inhibitory activity according to claim 1 for the preparation of health foods for the prevention and treatment of diabetes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210528272.3A CN115010785B (en) | 2022-05-16 | 2022-05-16 | Tetrapeptide with dipeptidyl peptidase-4 inhibitory activity and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210528272.3A CN115010785B (en) | 2022-05-16 | 2022-05-16 | Tetrapeptide with dipeptidyl peptidase-4 inhibitory activity and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115010785A true CN115010785A (en) | 2022-09-06 |
| CN115010785B CN115010785B (en) | 2023-05-12 |
Family
ID=83068693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210528272.3A Active CN115010785B (en) | 2022-05-16 | 2022-05-16 | Tetrapeptide with dipeptidyl peptidase-4 inhibitory activity and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115010785B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106905416A (en) * | 2017-04-24 | 2017-06-30 | 南京中医药大学 | With active peptide for suppressing dipeptidyl peptidase 4 and preparation method and application |
| CN109021074A (en) * | 2018-08-31 | 2018-12-18 | 华南理工大学 | A kind of heptapeptide improving diabetes and senile dementia symptom |
| CN110590905A (en) * | 2019-05-31 | 2019-12-20 | 华南理工大学 | Hypoglycemic hexapeptide |
| CN113801192A (en) * | 2021-08-31 | 2021-12-17 | 华南理工大学 | Tetrapeptide for inhibiting dipeptidyl peptidase IV and application thereof |
-
2022
- 2022-05-16 CN CN202210528272.3A patent/CN115010785B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106905416A (en) * | 2017-04-24 | 2017-06-30 | 南京中医药大学 | With active peptide for suppressing dipeptidyl peptidase 4 and preparation method and application |
| CN109021074A (en) * | 2018-08-31 | 2018-12-18 | 华南理工大学 | A kind of heptapeptide improving diabetes and senile dementia symptom |
| CN110590905A (en) * | 2019-05-31 | 2019-12-20 | 华南理工大学 | Hypoglycemic hexapeptide |
| CN113801192A (en) * | 2021-08-31 | 2021-12-17 | 华南理工大学 | Tetrapeptide for inhibiting dipeptidyl peptidase IV and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 刘轶等: "胶原ACE抑制肽研究进展", 《食品科学》 * |
| 王贝贝等: "模拟胃肠消化对羊皮胶原肽抗氧化活性的影响及其消化保护分析", 《食品科学》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115010785B (en) | 2023-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jin et al. | Identification of novel DPP–IV inhibitory peptides from Atlantic salmon (Salmo salar) skin | |
| US5364851A (en) | Conformationally restricted biologically active peptides, methods for their production and uses thereof | |
| Ma et al. | Three novel ACE inhibitory peptides isolated from Ginkgo biloba seeds: Purification, inhibitory kinetic and mechanism | |
| US20050037430A1 (en) | Methods and uses for protein breakdown products | |
| US20090035287A1 (en) | Atrial natriuretic peptide (anp) splice variants and methods of using same | |
| CN117285596B (en) | Hexapeptide RL6 with uric acid reducing function and application thereof | |
| CN115385986B (en) | Small molecule peptide with xanthine oxidase inhibitory activity and application thereof | |
| US20090227505A1 (en) | Methods and uses for protein breakdown products | |
| Zhao et al. | Exploration, sequence optimization and mechanism analysis of novel xanthine oxidase inhibitory peptide from Ostrea rivularis Gould | |
| CN110590905B (en) | Hypoglycemic hexapeptide | |
| CN107868124B (en) | Zein anti-inflammatory polypeptide and preparation method thereof | |
| EP3321279A1 (en) | Exenatide modifier and use thereof | |
| CN111518164A (en) | ACE inhibitory peptide P2, application thereof and preparation method thereof | |
| Lang et al. | Purification, identification, and molecular mechanism of DPP‐IV inhibitory peptides from defatted Antarctic krill powder | |
| WO2022134395A1 (en) | Novel bh3 mimetic peptide analog inhibiting ptp1b activity and application thereof | |
| CN115010785A (en) | Tetrapeptide with dipeptidyl peptidase-4 inhibitory activity and application thereof | |
| CN106905416B (en) | Active peptide capable of inhibiting dipeptidyl peptidase-4 and preparation method and application thereof | |
| CN106905417B (en) | Dipeptidyl peptidase-4 inhibitory peptide, and preparation method and application thereof | |
| CN109369782A (en) | A kind of decapeptide improving diabetes and senile dementia | |
| CN117003845B (en) | Millet prolamin peptide and its use in treating hyperlipoidemia | |
| CN115109117B (en) | Multifucus phycoerythrin angiotensin converting enzyme inhibitory peptide and preparation method and application thereof | |
| CN109021074B (en) | Heptapeptide for improving symptoms of diabetes and senile dementia | |
| CN109912688B (en) | PTP1B polypeptide inhibitors and preparation method and application thereof | |
| WO2018001273A1 (en) | Peptide or salt thereof, preparation method therefor, and use thereof in preparation of medicine for preventing and/or treating liver damage | |
| CN114315965A (en) | Anti-obesity peptides and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240222 Address after: No. 366, Building B, Dongsen Commercial Plaza, No. 379 Yande Road, Lihai Street, Yuecheng District, Shaoxing City, Zhejiang Province, 312000 Patentee after: Shaoxing Gaodeng Baitai Biopharmaceutical Co.,Ltd. Country or region after: China Address before: 214100 7th floor, South Building, No. 898, Tongsha Road, Liangxi District, Wuxi City, Jiangsu Province Patentee before: Jiangnan University Country or region before: China |